Rabusertib (LY2603618, IC-83) is a highly selective Chk1inhibitor with potential anti-tumor activity in a cell-free assay. IC50=7 nM, showing approximately 100-fold more potent against Chk1 than against any of the other protein kinases evaluated. Rabusertib (LY2603618) induces cell cycle arrest, DNA damage response and autophagyin cancer cells. Rabusertib (LY2603618) induces bak-dependent apoptosisin AML cell lines.
Price | 1.119,00 RON (preturile sunt fara TVA) |
---|---|
Description |
Rabusertib (LY2603618, IC-83) is a highly selective Chk1inhibitor with potential anti-tumor activity in a cell-free assay. IC50=7 nM, showing approximately 100-fold more potent against Chk1 than against any of the other protein kinases evaluated. Rabusertib (LY2603618) induces cell cycle arrest, DNA damage response and autophagyin cancer cells. Rabusertib (LY2603618) induces bak-dependent apoptosisin AML cell lines. |